Show simple item record

dc.contributor.authorSonnenblick, A
dc.contributor.authorBailey, A
dc.contributor.authorUziely, B
dc.contributor.authorUntch, M
dc.contributor.authorSmith, I
dc.contributor.authorGianni, L
dc.contributor.authorBaselga, J
dc.contributor.authorJackisch, C
dc.contributor.authorCameron, D
dc.contributor.authorBell, R
dc.contributor.authorZardavas, D
dc.contributor.authorAl-Sakaff, N
dc.contributor.authorGelber, RD
dc.contributor.authorDowsett, M
dc.contributor.authorLeyland-Jones, B
dc.contributor.authorPiccart-Gebhart, MJ
dc.contributor.authorDE Azambuja, E
dc.date.accessioned2019-07-04T12:47:04Z
dc.date.issued2019-02
dc.identifier.citationAnticancer research, 2019, 39 (2), pp. 797 - 802
dc.identifier.issn0250-7005
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3281
dc.identifier.eissn1791-7530
dc.identifier.doi10.21873/anticanres.13177
dc.description.abstractBACKGROUND/AIM:This study sought to determine whether an autoimmune background could identify patients with HER2-positive early breast cancer (EBC) who derive differential benefit from primary adjuvant trastuzumab-based therapy. PATIENTS AND METHODS:HERA is an international randomized trial of 5,102 women with HER2-positive EBC, who were enrolled to either receive adjuvant trastuzumab or not. In this exploratory analysis, the interaction between autoimmune history and the magnitude of trastuzumab benefit was evaluated. RESULTS:A total of 5,099 patients were included in the current analysis. Among them, 325 patients (6.4%) had autoimmune disease history, 295 of whom had active disease. Patients were randomly assigned to trastuzumab or no-trastuzumab groups. Similar reductions in the risk of events in patients with and without autoimmune history were observed (interaction p=0.95 for disease-free survival, and p=0.62 for overall survival). CONCLUSION:No evidence of a differential benefit from trastuzumab in patients with a medical history of autoimmune disease was found.
dc.formatPrint
dc.format.extent797 - 802
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectAutoimmune Diseases
dc.subjectDisease-Free Survival
dc.subjectTreatment Outcome
dc.subjectChemotherapy, Adjuvant
dc.subjectProportional Hazards Models
dc.subjectRisk
dc.subjectInternational Cooperation
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectTrastuzumab
dc.subjectAntineoplastic Agents, Immunological
dc.titleAutoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.
dc.typeJournal Article
dcterms.dateAccepted2019-01-10
rioxxterms.versionofrecord10.21873/anticanres.13177
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfAnticancer research
pubs.issue2
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume39
pubs.embargo.termsNo embargo
icr.researchteamMedicine (RMH Smith Cunningham)en_US
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorSmith, Ianen
dc.contributor.icrauthorDowsett, Mitchen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record